Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation
and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and
tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the
study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate
the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension
to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as
monotherapy will be available to those who are currently being treated in either Part 1 or
Part 2 of this study at the time of protocol Amendment 9, v10.0.